Trial
NCT03773133
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Small Cell Lung Cancer and Breast Cancer
Intervention
Satoreotide tetraxetan
Why stopped
High number of screen failures
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-13